HDAC9 and neoplasm: In the treatment of PDAC, multiple HDAC inhibitors have demonstrated anti-tumor efficacy in vivo as well as in mouse models but failed in clinical trials [20,42], presumably indicating that HDACis might not be suitable for monotherapy.